SYNGENE - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.4
| Stock Code | SYNGENE | Market Cap | 16,881 Cr. | Current Price | 419 ₹ | High / Low | 761 ₹ |
| Stock P/E | 44.0 | Book Value | 115 ₹ | Dividend Yield | 0.30 % | ROCE | 12.8 % |
| ROE | 9.78 % | Face Value | 10.0 ₹ | DMA 50 | 475 ₹ | DMA 200 | 593 ₹ |
| Chg in FII Hold | -1.35 % | Chg in DII Hold | 1.21 % | PAT Qtr | 68.7 Cr. | PAT Prev Qtr | 66.2 Cr. |
| RSI | 41.4 | MACD | -18.8 | Volume | 9,08,300 | Avg Vol 1Wk | 28,94,356 |
| Low price | 381 ₹ | High price | 761 ₹ | PEG Ratio | 34.1 | Debt to equity | 0.07 |
| 52w Index | 9.87 % | Qtr Profit Var | -44.2 % | EPS | 8.22 ₹ | Industry PE | 52.3 |
🔎 Analysis: SYNGENE is trading at ₹419, well below its 50 DMA (₹475) and 200 DMA (₹593), showing short-term weakness. RSI at 41.4 is near oversold territory, while MACD (-18.8) signals bearish momentum. Volume is significantly lower than the 1-week average, indicating weak participation. Intraday trade is possible only with strict stop-loss discipline.
💰 Optimal Buy Price: ₹410–₹420 if price stabilizes near support.
📈 Profit Exit Levels: ₹435 (first target), ₹450 (second target near resistance).
📉 Stop-Loss: ₹405 to protect against downside risk.
⏱️ If Already Holding: Exit near ₹435 if momentum slows. Trail stop-loss below ₹410. Exit immediately if price breaks ₹405 with strong volume.
✅ Positive
- Quarterly PAT improved slightly (₹68.7 Cr vs ₹66.2 Cr).
- DII holdings increased (+1.21%), reflecting domestic investor confidence.
- Low debt-to-equity ratio (0.07) shows financial stability.
- Book value at ₹115 provides some valuation support.
⚠️ Limitation
- Stock P/E (44.0) is below industry average (52.3) but still expensive given weak earnings.
- ROCE (12.8%) and ROE (9.78%) are modest, limiting efficiency.
- PEG ratio (34.1) suggests significant overvaluation relative to growth.
- Momentum indicators (RSI, MACD) remain weak.
📉 Company Negative News
- Quarterly profit variation (-44.2%) highlights earnings pressure.
- FII holdings decreased (-1.35%), showing reduced foreign confidence.
📊 Company Positive News
- Slight sequential PAT improvement shows resilience.
- DII inflows support domestic sentiment.
- Low debt-to-equity ratio enhances financial stability.
💊 Industry
- Biotech & pharma services sector average P/E is 52.3, higher than SYNGENE’s 44.0.
- Sector growth remains tied to R&D outsourcing and global pharma demand.
📝 Conclusion
SYNGENE shows weak short-term momentum with RSI and MACD in bearish zones, and declining profit variation. Fundamentals are modest, with low debt and DII inflows as positives. Intraday traders should only consider entry near ₹410–₹420 with strict stop-loss at ₹405. Profit-taking should be quick at ₹435–₹450. Momentum remains fragile, so cautious trading is advised.
Would you like me to extend this into a peer benchmarking overlay with Biocon, Divi’s Labs, and Laurus Labs? That way, you’ll see whether SYNGENE’s intraday weakness is stock-specific or part of a broader biotech/pharma services sector trend.